A groundbreaking retrospective chart review, recently published in the prestigious Journal of Clinical Medicine, reveals compelling real-world evidence that deprescribing glucose-lowering medications in patients with type 2 diabetes can be both feasible and safe. This research highlights the significant role that lifestyle-informed care plays within primary care settings, suggesting a paradigm shift from medication reliance toward holistic patient empowerment.
The study examined electronic health records of 650 adults diagnosed with type 2 diabetes, all receiving care at two primary care practices that incorporate lifestyle medicine principles into their routine clinical interactions. These principles emphasize comprehensive lifestyle modification, including nutritional guidance, physical activity, and behavioral changes, aimed at improving metabolic health. Within this cohort, researchers employed a structured deprescribing framework to systematically identify cases where diabetes medications were reduced or fully discontinued following sustained improvements in metabolic parameters.
Remarkably, the investigators confirmed 41 such cases where deprescribing occurred safely, translating to approximately 6.3% of the studied population. While this percentage may appear modest at first glance, it is critical to contextualize these results: the medication reductions did not arise from intensive lifestyle intervention programs or specialty clinics but emerged organically during routine primary care visits. Patients only required a minimum of two clinical encounters to be eligible for inclusion, underscoring the scalability and natural integration of lifestyle medicine in everyday clinical practice.
If extrapolated to the estimated 38 million Americans living with type 2 diabetes, even this modest 6% deprescribing rate could herald transformative public health benefits. Millions might potentially reduce their medication burden, lower healthcare costs, and diminish the risk of adverse medication-related side effects. This finding fuels optimism for the evolution of diabetes management strategies, aligning therapeutic goals more closely with patient-centered, sustainable care.
Dr. Gia Merlo, a leading expert in lifestyle medicine and professor in the Department of Psychiatry at NYU Grossman School of Medicine, reflected on these outcomes, emphasizing that the study advances understanding of how deprescribing can be effectively and safely conducted in primary care. She highlighted that when lifestyle medicine principles are embedded into routine care, medication reduction can become a meaningful, patient-centered endpoint complementing traditional glycemic control measures.
Among the patients who experienced deprescribing and had subsequent follow-up data, the study documented clinically significant improvements in key metabolic markers. On average, participants showed a reduction in body mass index (BMI) by 2.2 kg/m², alongside a notable decline in blood glucose levels averaging 50.5 mg/dL. These changes were statistically significant, reinforcing the physiological benefits of lifestyle intervention as a foundation for medication tapering strategies.
The medication adjustments most frequently observed were a 34% reduction in metformin dosage, 19.5% metformin discontinuation, and a 19.5% reduction in insulin dosage. Importantly, three adverse events were recorded during the chart review, but none were attributed to the deprescribing process itself within the lifestyle-informed primary care context. This safety profile is encouraging as it underscores the potential for safe medication optimization given appropriate clinical frameworks and patient monitoring.
Interestingly, explicit documentation of lifestyle changes was only found in just over half of the deprescribed cases, with diet modification and increased physical activity being the most common interventions noted. The researchers cautioned that these figures likely underestimate true patient engagement with lifestyle modifications, reflecting documentation practices rather than an absence of behavioral change. This underscores the importance of improved clinical documentation and patient-provider communication to capture holistic treatment progress effectively.
This study breathes new life into the concept of deprescribing in the field of diabetes care, demonstrating that lifestyle modifications can serve as both preventive and therapeutic measures. Adopting lifestyle medicine protocols that facilitate medication reduction not only enhances patient autonomy but also aligns with broader healthcare objectives targeting cost reduction and improved quality of life for individuals living with chronic illness.
Looking forward, Dr. Micaela C. Karlsen, Senior Director of Research and Quality at the American College of Lifestyle Medicine (ACLM), called for continued investigation into deprescribing outcomes within lifestyle medicine–informed care models. She underscored the potential for implementing deprescribing protocols specifically designed to respond to lifestyle-driven improvements, positioning this approach as a pathway toward advancing evidence-based, patient-centered treatment frameworks in chronic disease management.
The American College of Lifestyle Medicine, which supports this research agenda, is a pioneering medical professional society devoted to the transformation of healthcare. By emphasizing lifestyle as the foundation of a value-based, equitable healthcare delivery system, the ACLM aims to address the root causes of chronic diseases through modifiable risk factors. Since 2004, the organization has delivered over 1.2 million hours of lifestyle medicine education to health professionals, actively advancing clinical practice and reimbursement frameworks that support sustainable patient outcomes.
This study marks an important milestone in chronic disease management, providing actionable evidence that deprescribing glucose-lowering medications is not only achievable but can thrive under routine primary care settings that prioritize lifestyle modification. As healthcare systems grapple with the escalating burden of type 2 diabetes, integrating lifestyle-driven deprescribing protocols could catalyze a shift toward more efficient, personalized, and safer care trajectories for millions worldwide.
Subject of Research: Deprescribing glucose-lowering medications in patients with type 2 diabetes within lifestyle-informed primary care settings.
Article Title: Deprescribing Following Access to Lifestyle Treatment: A Retrospective Chart Review of Primary Care Outcomes in Patients with Type 2 Diabetes
News Publication Date: 27-Mar-2026
Web References:
https://doi.org/10.3390/jcm15072561
https://www.mdpi.com/2077-0383/15/7/2561
https://www.mdpi.com/2077-0383/15/7/2524
Keywords: Type 2 diabetes, deprescribing, lifestyle medicine, primary care, glucose-lowering medications, metformin reduction, insulin dose reduction, BMI improvement, patient-centered care, chronic disease management.
